Outset Medical Sets Out To Upend Dialysis

Leslie Trigg didn’t design her Medtech career, but her pursuit of the right opportunities led her to a series of wildly successful start-ups including her recent venture, Outset Medical, creator of an innovative new dialysis system.
​
The first-time CEO recognized Outset’s potential as it seeks to bring change to an industry that has remained the same for decades. In this podcast, Trigg shares her early thoughts about Outset’s potential and what she’s learned along the way.
Trigg also takes the time to share some insights on what makes being a Medtech leader most meaningful.

Listen here: http://healthegy.com/outset-ceo-trigg-talks-dialysis-fundraising-and-what-makes-a-medtech-career-matter/

BEND, Ore. - St. Charles Bend announced Monday it is the first hospital in Oregon to offer a new treatment program for patients at risk for stroke due to blockages in their neck arteries.

The minimally invasive procedure, called TransCarotid Artery Revascularization or TCAR, utilizes a new FDA-approved neuroprotection system that temporarily reverses blood flow in the artery during the procedure. Dangerous bits of plaque and blood clots that could dislodge and otherwise travel to the brain and cause a stroke are safely diverted away while a dedicated transcarotid stent is inserted to open and stabilize the blockage. 

Prior to TCAR, the main treatment option for severe carotid artery disease was an open surgical procedure called carotid endarterectomy.

Read More: ​http://www.ktvz.com/news/st-charles-first-oregon-hospital-to-offer-carotid-artery-procedure/499916097

Q1 Cash Balance of $156.9M — Cash Through Q3 2019

Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints

Focused on Immuno-Oncology Pipeline and Celgene Collaboration Programs

REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter financial results.  As of March 31, 2017, cash, and short-term investments totaled $156.9 million.

"We continue to drive forward our strong immuno-oncology R&D pipeline, including anti-TIGIT, wholly-owned GITRL-Fc trimer, and our novel undisclosed immuno-oncology discovery programs — as well as advancing programs in our Celgene collaboration to $98 million in potential opt-in payments within the next two years," said Paul J. Hastings, OncoMed's Chairman and CEO.  "With more than two years cash, we are dedicated to advancing our pipeline while exploring partnering opportunities to advance all of our programs."

Read More: www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1025195

Phase 1a Study Will Assess Novel Checkpoint Inhibitor as a Single Agent in Solid Tumors

REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, announced today that the first patient has been dosed in the company's Phase 1a clinical trial of anti-TIGIT (OMP-313M32).  Anti-TIGIT is an investigational immuno-oncology therapeutic candidate intended to block suppression of the immune system in tumors and enable immune system anti-tumor activity, similar to marketed checkpoint inhibitors that target the PD-L1-PD-1 axis.
​
"The first wave of immuno-oncology agents demonstrated that disabling immune suppression mechanisms in tumors can enable the body's immune system to fight cancers with good efficacy. Still, available immunotherapies have limited results for many cancer patients, and there remains a pressing need for new agents and combinations to improve outcomes," said Johanna Bendell, M.D., Associate Director of the Drug Development Program at Sarah Cannon Research Institute and a lead investigator for the Phase 1a anti-TIGIT study.  "The immuno-suppressive receptor TIGIT is expressed on many different tumor types, giving us reason to believe that an anti-TIGIT antibody, such as OncoMed's OMP-313M32, has potential for broad activity in cancer patients. I look forward to seeing its performance in the clinic."

Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1024817

Outset Medical announced it received $76.5 million in Series C equity funding. A new investor, funds advised by T. Rowe Price Associates Inc., led the round, which also included participation from existing investors Fidelity Management & Research Company, Partner Fund Management LP, Warburg Pincus, Perceptive Advisors and The Vertical Group.

Outset’s technology, the Tablo Hemodialysis System, is aimed at clinics who want to develop the self-care option for patients. It can also be used in hospitals and skilled nursing facilities.

The company will use proceeds from the financing to expand the commercial introduction of the Tablo System in acute and chronic care markets in the United States.

Read More: ​http://www.nephrologynews.com/outset-medical-gets-financing-expand-introduction-tablo-dialysis-machine/

Financing to Expand U.S. Commercial Introduction and Manufacturing

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the $13 billion global dialysis market, today announced $76.5 million in Series C equity funding. A new investor, funds advised by T. Rowe Price Associates, Inc., led the round, which also included participation from existing investors Fidelity Management & Research Company, Partner Fund Management LP, Warburg Pincus, Perceptive Advisors and The Vertical Group.

Outset’s technology, the Tablo™ Hemodialysis System, is the first novel dialysis system to reach the U.S. market in more than 15 years. The system can be used flexibly across a range of clinical settings from dialysis clinics to hospitals and skilled nursing facilities. The company will use proceeds from the financing to expand the commercial introduction of the Tablo System in acute and chronic care markets in the United States.

Read More: http://www.businesswire.com/news/home/20170503005383/en/Outset-Medical-Announces-76.5-Million-Funding-Innovative